US FDA invites feedback on IOM advice to scrap 510(k) process
This article was originally published in SRA
The US Food and Drug Administration is inviting feedback from the public on a controversial report by Institute of Medicine that is calling on the agency to abandon its pre-market notification process for clearing most medium- and low-risk medical devices in favour of an entirely new framework1,2.
You may also be interested in...
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.